- Home
- ARMN vs CDTX Comparison
ARMN vs CDTX Comparison
Compare ARMN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- CDTX
- Stock Information
- Founded
- ARMN 1992
- CDTX 2012
- Country
- ARMN Canada
- CDTX United States
- Employees
- ARMN 3485
- CDTX N/A
- Industry
- ARMN
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARMN
- CDTX Health Care
- Exchange
- ARMN Nasdaq
- CDTX Nasdaq
- Market Cap
- ARMN 2.0B
- CDTX 1.6B
- IPO Year
- ARMN N/A
- CDTX 2015
- Fundamental
- Price
- ARMN $9.90
- CDTX $95.25
- Analyst Decision
- ARMN Strong Buy
- CDTX Strong Buy
- Analyst Count
- ARMN 1
- CDTX 11
- Target Price
- ARMN $17.00
- CDTX $80.90
- AVG Volume (30 Days)
- ARMN 2.4M
- CDTX 916.7K
- Earning Date
- ARMN 11-11-2025
- CDTX 11-06-2025
- Dividend Yield
- ARMN N/A
- CDTX N/A
- EPS Growth
- ARMN N/A
- CDTX N/A
- EPS
- ARMN 0.02
- CDTX N/A
- Revenue
- ARMN $646,783,000.00
- CDTX N/A
- Revenue This Year
- ARMN $49.45
- CDTX N/A
- Revenue Next Year
- ARMN $11.08
- CDTX N/A
- P/E Ratio
- ARMN $383.54
- CDTX N/A
- Revenue Growth
- ARMN 38.72
- CDTX N/A
- 52 Week Low
- ARMN $3.29
- CDTX $10.14
- 52 Week High
- ARMN $10.07
- CDTX $90.85
- Technical
- Relative Strength Index (RSI)
- ARMN 65.01
- CDTX 76.95
- Support Level
- ARMN $8.89
- CDTX $83.09
- Resistance Level
- ARMN $10.07
- CDTX $90.64
- Average True Range (ATR)
- ARMN 0.40
- CDTX 5.53
- MACD
- ARMN -0.06
- CDTX 2.79
- Stochastic Oscillator
- ARMN 84.60
- CDTX 94.76
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.